Drugs / SCT-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06846424 | Jun 2025 → Jun 2027 expected | fallopian tube carcinoma, ovarian cancer, peritoneal carcinoma | Shanghai Gynecologic Oncology Group | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCT-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06846424 ↗ |
| Modality | Cell therapy | “autologous-derived CAR-T cell products” NCT06846424 ↗ |
| Route | Other | “cohort 1 was the intraperitoneal route of administration” NCT06846424 ↗ |